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Trends in prevalence of blindness and distance and near 
vision impairment over 30 years: an analysis for the Global 
Burden of Disease Study
GBD 2019 Blindness and Vision Impairment Collaborators* on behalf of the Vision Loss Expert Group of the Global Burden of Disease Study†
Summary
Background To contribute to the WHO initiative, VISION 2020: The Right to Sight, an assessment of global vision 
impairment in 2020 and temporal change is needed. We aimed to extensively update estimates of global vision loss 
burden, presenting estimates for 2020, temporal change over three decades between 1990–2020, and forecasts 
for 2050.
Methods We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, 
to October, 2018. Only studies with samples representative of the population and with clearly defined visual acuity 
testing protocols were included. We fitted hierarchical models to estimate 2020 prevalence (with 95% uncertainty 
intervals [UIs]) of mild vision impairment (presenting visual acuity ≥6/18 and <6/12), moderate and severe vision 
impairment (<6/18 to 3/60), and blindness (<3/60 or less than 10° visual field around central fixation); and vision 
impairment from uncorrected presbyopia (presenting near vision <N6 or <N8 at 40 cm where best-corrected distance 
visual acuity is ≥6/12). We forecast estimates of vision loss up to 2050.
Findings In 2020, an estimated 43·3 million (95% UI 37·6–48·4) people were blind, of whom 23·9 million (55%; 
20·8–26·8) were estimated to be female. We estimated 295 million (267–325) people to have moderate and severe 
vision impairment, of whom 163 million (55%; 147–179) were female; 258 million (233–285) to have mild vision 
impairment, of whom 142 million (55%; 128–157) were female; and 510 million (371–667) to have visual impairment 
from uncorrected presbyopia, of whom 280 million (55%; 205–365) were female. Globally, between 1990 and 2020, 
among adults aged 50 years or older, age-standardised prevalence of blindness decreased by 28·5% (–29·4 to –27·7) 
and prevalence of mild vision impairment decreased slightly (–0·3%, –0·8 to –0·2), whereas prevalence of moderate 
and severe vision impairment increased slightly (2·5%, 1·9 to 3·2; insufficient data were available to calculate this 
statistic for vision impairment from uncorrected presbyopia). In this period, the number of people who were blind 
increased by 50·6% (47·8 to 53·4) and the number with moderate and severe vision impairment increased by 91·7% 
(87·6 to 95·8). By 2050, we predict 61·0 million (52·9 to 69·3) people will be blind, 474 million (428 to 518) will have 
moderate and severe vision impairment, 360 million (322 to 400) will have mild vision impairment, and 866 million 
(629 to 1150) will have uncorrected presbyopia.
Interpretation Age-adjusted prevalence of blindness has reduced over the past three decades, yet due to population 
growth, progress is not keeping pace with needs. We face enormous challenges in avoiding vision impairment as the 
global population grows and ages.
Funding Brien Holden Vision Institute, Fondation Thea, Fred Hollows Foundation, Bill & Melinda Gates Foundation, 
Lions Clubs International Foundation, Sightsavers International, and University of Heidelberg.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license. 
Introduction
VISION 2020: The Right to Sight, a joint global initiative 
for the elimination of avoidable blindness between 
WHO and the International Agency for the Prevention 
of Blindness, has galvanised efforts to systematically 
eliminate avoidable blindness.1,2 Furthermore, the adop­
tion of the resolution Towards universal eye health: a global 
action plan 2014–2019 by the World Health Assembly 
renewed ideals and strategies for Member States to 
amplify initiatives to prevent vision impairment and 
promote low vision rehabilitation in their populations.3
The Vision Loss Expert Group (VLEG) populates and 
curates the Global Vision Database, a continuously 
updated, comprehensive, online database storing world­
wide ophthalmic epidemiological information. In a 
previous report, we estimated that in 2015, 36·0 million 
people were blind, 217 million had moderate and severe 
vision impairment, 188 million had mild vision 
impairment, and 667 million additional people (aged 
≥50 years) had vision impairment from uncorrected 
presbyopia.4 These 2015 estimates were used for the 
World report on vision, published by WHO in 2019.5 We 
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subsequently provided country­specific data online, 
searchable by level of vision impairment, age, and sex.
As countries progress on the spectrum of socio economic 
development and life expectancies increase, the disease 
burden is shifting from communicable conditions to non­
communicable and age­related con ditions. The blinding 
ophthalmic conditions that are manifesting in this so­called 
epidemiological transition6 include age­related cataract,7 
age­related macular degeneration,8 glaucoma,9 and diabetic 
retinopathy.10 Vision impairment and blindness are associ­
ated with reduced economic, educational, and employment 
opportunities,11–14 and increased risk of death.15,16 Further­
more, in older age, vision impairment not only signifi­
cantly affects quality of life17 (eg, the association between 
vision impairment and depression18–20) but also amplifies 
comorbidities such as cognitive impairment21 and risk 
of falls.22
Our 2015 report concentrated on blindness and 
moderate and severe vision impairment, with little 
data pertaining to mild vision impairment and vision 
impairment from uncorrected presbyopia. Since then, in 
collaboration with the Global Burden of Disease Study 
(GBD), the Global Vision Database has been extensively 
updated and revised with increased granularity of the 
available worldwide ophthalmic epidemiological infor­
mation, permitting a more precise estimate of the global 
vision loss burden in 2020 and assessment of temporal 
changes. Additionally, we can describe vision loss in 
terms of years lived with disability (YLDs).
Methods
Input data
Preparation of data included first a systematic review of 
published population­based studies of vision impairment 
and blindness by the VLEG, that also included grey 
literature sources. Eligible studies from this review were 
then combined with data from Rapid Assessment of 
Avoidable Blindness (RAAB) studies by VLEG and finally 
data from the US National Health and Nutrition 
Examination survey and the WHO Study on Global 
Ageing and Adult Health were contributed by the GBD 
team. These stages are explained in more detail as follows.
In this study, we used population­representative studies 
as data sources for modelling of vision impairment; more 
detailed methods are in the appendix (pp 3–25). The VLEG 
serially systematically reviewed literature published 
between Jan 1, 1980, and Oct 1, 2018, by commissioning 
the York Health Economics Consortium (University of 
York, York, UK) to search Embase, SciELO, MEDLINE, 
WHO Library Database, and OpenGrey, and additional 
grey literature sources (a detailed search strategy is given 
in the appendix [pp 4–24]). After title and abstract 
screening, abstracts were sent to regional committees of 
VLEG members to assess quality and make final inclusion 
decisions. In total, VLEG identified 137 studies and 
extracted data from 70 studies in their 2010 review, and 
a further 67 studies in their 2014–18 review. Studies 
were primarily national and subnational cross­sectional 
surveys. We included RAAB surveys, which sampled 
individuals aged 50–99 years in low­income and middle­
income settings. Additionally, the VLEG commissioned 
the preparation of 5­year age­disaggregated RAAB data 
from the RAAB repository. We included studies that met 
the following criteria: visual acuity data had to be 
measured using a test chart that could be mapped to the 
Snellen scale, and the sample had to be representative 
of the population. Self­report of vision loss was 
excluded. We used International Classification of Diseases 
11th edition criteria for vision loss, as used by WHO, 
which categorises people according to vision in the better 
Research in context
Evidence before this study
The Vision Loss Expert Group (VLEG) previously published 
global, regional, and country-level estimates of mild or more 
severe distance vision impairment from 1990 to 2015. They 
found an overall decrease in age-standardised prevalence of 
distance vision but an increase in total people with vision loss. 
In collaboration with the VLEG, the Global Burden of Disease 
Study (GBD) has produced annual updates of estimates of 
vision impairment, most recently in 2019. An important 
contribution to the WHO initiative, VISION 2020: The Right to 
Sight, these studies are unique in  providing granular estimates 
that are sex, age, and country specific, and also assess 
temporal trends.
Added value of this study
This updated assessment of global vision impairment 
contributes to VISION 2020: The Right to Sight by providing 
up-to-date global and regional sex-specific and age-specific 
estimates of vision impairment, analyses of how vision 
impairment rates and cases have changed over time, and 
projections by region to 2050. The current study also allows us 
to assess the World Health Assembly 2013 resolution to 
decrease avoidable moderate or worse distance vision 
impairment by 25% from 2010 to 2019. Our results suggest 
that total cases of moderate or worse distance vision have 
increased since 2010, and therefore, in terms of crude 
prevalence, the target was not reached.
Implications of all the available evidence
Despite a reduction in global age-standardised prevalence of 
blindness, the crude prevalence is increasing, and with an 
ageing and growing population, vision impairment remains an 
urgent and increasingly important public health priority. We are 
currently investigating the causes of vision impairment, 
and more directly assessing temporal changes in avoidable 
vision loss.
For the RAAB repository see 
http://raabdata.info
See Online for appendix
For more on country-specific 
data see http://atlas.iapb.org 
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eye on presentation, in which mild vision loss is defined 
as a visual acuity of 6/18 or better but less than 6/12, 
moderate vision loss as a visual acuity of 6/60 or better but 
less than 6/18, severe vision loss as a visual acuity of 3/60 
or better but less than 6/60 (hence our definition of 
moderate and severe vision loss is <6/18 to 3/60), and 
blindness as a visual acuity of less than 3/60 or less than 
10° visual field around central fixation (although the visual 
field definition is rarely used in population­based eye 
surveys). Vision impairment from uncorrected presbyopia 
was defined as presenting near vision of worse than N6 or 
N8 at 40 cm when best­corrected distance visual acuity 
was 6/12 or better. This definition was used to avoid 
double counting individuals with both distance and near 
vision impairment associated with non­refractive causes.4 
We included studies that measured either presenting 
vision loss, where visual acuity was measured using the 
usual corrective lenses an individual arrived wearing, or 
best­corrected vision loss, where correction using a lens or 
pinhole addressed any refractive error.
The data identification process is summarised in the 
appendix (pp 3–25, 93–100, 102).
Data preparation
First, we separated raw data into datasets including so­
called vision­loss envelopes for all­cause mild, moderate, 
and severe vision loss, and blindness. Studies that only 
reported male and female sex information combined were 
split into male­specific and female­specific datapoints by 
identifying within­study datapoints matched by age, year, 
and location that reported data for male and female 
prevalence separately, and then we used the log ratio of 
female to male prevalence from these studies as input 
data into a mixed­effects meta­regression tool developed 
by the Institute for Health Metrics and Evaluation (IHME) 
called MR­BRT (meta regression; Bayesian; regularised; 
trimmed). This tool was developed in part to allow for the 
ability to propagate between­study heterogeneity as part of 
uncertainty adjustments, and to allow trimming of outlier 
input data. A detailed description of MR­BRT has been 
published elsewhere.23 We used results from this model 
and demographic data on population by location 
to determine male and female prevalence of vision 
impairment. Next, we used MR­BRT to adjust non­
reference data to the reference definition of presenting 
vision data that fit within the WHO severity categories 
using data from studies that did not involve RAAB 
methods. We split data that spanned thresholds (either 
prevalence data for moderate and severe vision loss 
combined, or severe vision loss and blindness combined) 
into reference severity groups (moderate vision loss, 
severe vision loss, blindness) using a log ratio meta­
regression with a cubic spline on age with linear tails. The 
input data for this meta­regression came from studies that 
provided matched age, year, sex, and location data for each 
severity level (eg, moderate vision loss and severe vision 
loss separately). If input data were collected for age ranges 
of greater than 25 years, these data were split into 5­year 
age bins. More detailed information on age­splitting and 
adjustment of best­corrected visual acuity data to the 
reference definitions is in the appendix (pp 25–26).
Disease Modelling Meta-Regression 2.1 modelling
Disease Modelling Meta­Regression (DisMod­MR) 2.1 
modelling is described in detail elsewhere.24 Briefly, 
this is a Bayesian mixed­effects meta­regression tool 
developed for GBD non­fatal disease modelling. It is 
based on a compartmental model with age integration in 
which individuals can move from a state of health to 
disease, and either back to health or to death. For vision 
modelling, no fatal component exists and estimates are 
made for prevalence only. For DisMod modelling, we 
used all input data from all locations in a mixed­effects 
non­linear model for a global estimate of disease burden. 
We used model outputs (global fit plus fixed effects plus 
random effects) in a cascade as a prior for estimates in the 
seven GBD super­regions, which in turn were used as 
priors for regional estimates, and then country estimates, 
and finally subnational estimates for a subset of 
21 countries. Final estimates for each geographical level 
were calculated by aggregation, where the country final 
estimate was the sum of subnational estimates, the 
regional final estimate was the sum of country final 
estimates, and the super­region final estimate was the 
sum of the regional final estimates. We used the GBD 
classification of countries and territories by region and 
super­region, a list of which is in the appendix (pp 28–29). 
We only present data by region in this Article.
Modelling and post-processing steps
We ran DisMod­MR 2.1 models for all vision loss 
severity categories. We used final estimates for vision 
loss to calculate YLDs on the basis of disability weights 
assigned to each severity of vision loss, and, finally, 
adjusted for comorbidity with any causes of non­fatal 
health loss.25 The health states and corresponding 
disability weights for vision are given in the appendix 
(p 101). We used YLD data for 2019, because these were 
the most recent data available.
Extrapolation, age-standardisation, and forecasting for 
2020 and 2050 estimates
Final estimates for GBD 2019 are for the years 1990–2019. 
To estimate the number of individuals for each severity 
level for the year 2020, we multiplied 1000 draws of 
estimated prevalence from GBD 2019 for each location by 
the 2020 population estimates for each location to calculate 
the number of affected individuals and 95% uncertainty 
intervals (UIs) in 2020. We age­standardised our estimates 
using the GBD standard population (a more detailed 
description is in the appendix [p 26]).26 We forecasted total 
cases of vision loss by severity for the years 2030, 2040, 
and 2050. These estimates were made for GBD regions 
and globally. We generated forecasts of age­specific rates 
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using age­specific prevalence rates for the years 1990, 
1995, 2000, 2005, 2010, 2015, and 2019 as input data into a 
regression analysis with year, region, and age as predictors. 
We included an interaction term between region and year, 
and a cubic spline on age. We ran sex­specific regression 
models 1000 times and used the resulting coefficients to 
predict rates in the years 2030, 2040, and 2050. We 
multiplied the predicted rates by forecasted population26 
for each region to obtain an estimated case number, 
and then aggregated these estimates to obtain global 
estimates. Finally, estimates were collapsed to mean and 
95% UIs.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results 
528 data sources were used to calculate the prevalence 
of vision loss categories, 243 (46%) of which were RAAB 
studies. Maps showing the distribution of RAAB and 
non­RAAB sources by region are in the appendix (p 111). 
44 (18%) of 243 RAAB studies were national in scope 
and the remaining 199 (82%) were subnational. 52 (18%) 
of 285 non­RAAB studies were nationally representative. 
Among all sources (both non­RAAB and RAAB), 
485 sources included data for blindness, 445 sources 
included data for moderate and severe vision 
impairment, 59 sources included data for mild vision 
impairment, and 25 sources included prevalence of 
vision impairment from uncorrected presbyopia.
Globally, 43·3 million (95% UI 37·6–48·4) people were 
estimated to be blind in 2020 (crude prevalence 5·49 
[4·76–6·13] per 1000), of whom 23·9 million (55%; 
20·8–26·8) were female (table 1; appendix p 105). 
In 2020, we estimated that the largest number of 
people with blindness resided in south Asia, followed by 
east Asia and southeast Asia (table 1). The crude 
prevalence of blindness ranged from 1·94 (95% UI 
1·70–2·18) cases per 1000 in high­income North America 
to 8·75 (7·58–9·82) cases per 1000 in southeast Asia 
(appendix p 105). The age­standardised prevalence of 
blindness ranged from 1·24 (1·09–1·39) cases per 1000 
people in high­income North America to 11·1 (9·52–12·6) 
per 1000 in western sub­Saharan Africa (table 1).
We estimated that moderate and severe vision 
impairment affected 295 million (95% UI 267–325) 
people in 2020 (table 1), with 37·4 (33·9–41·2) cases per 
1000 people in the global population, of whom 163 million 
(55%; 147–179) were female (appendix p 105). Of this 
category of vision loss, 260 million (232–289) people 
were moderately vision impaired and 34·8 million 
(30·7–39·3) were severely vision impaired. The largest 
number of people with moderate and severe vision 
impairment also resided in south Asia, followed by east 
Asia, and southeast Asia (table 1).
We estimated 258 million (95% UI 233–285) people 
were affected by mild vision impairment in 2020 
(crude prevalence 32·7 [29·5–36·2] cases per 1000), of 
whom 142 million (55%; 128–157) were female (table 2; 
appendix p 106).
We estimated 510 million (95% UI 371–667) people 
were affected by vision impairment from uncorrected 
presbyopia in 2020 (crude prevalence 64·6 [47·1–84·5] 
cases per 1000), of whom 280 million (55%; 205–365) 
were female (table 2; appendix p 106). Among those 
aged 50 years and older, 221 (155–296) individuals per 
1000 population had vision impairment from uncorrected 
presbyopia (appendix p 107). As with blindness and 
moderate and severe vision impair ment, most of those 
with mild vision impairment and vision impair ment from 
uncorrected presbyopia resided in south Asia, followed by 
east Asia and southeast Asia (table 2).
In 2020, age­standardised prevalence for all severities 
of vision impairment was higher in females aged 
50 years and older than in males of the same age group 
(difference between means and 95% UIs for blindness: 
0·00212 [0·00167–0·00265]; moderate and severe vision 
impair ment: 0·0121 [0·0106–0·0137]; mild: 0·0114 
[0·00969–0·0130]; and due to presbyopia: 0·0215 
[0·0148–0·0286]). This between­sex difference was 
largest for vision impairment from presbyopia, and 
smallest for blindness.
We estimated that in 2020 the population aged 50 years 
and older (24·1% of the global population) accounted for 
33·6 million (78%; 95% UI 28·6–38·5) of 43·3 million 
people who were blind, 206 million (70%; 182–233) of 
295 million people with moderate and severe vision 
impairment, 143 million (55%; 122–163) of 258 million 
people with mild vision impairment, and 419 million (82·2%; 
295–562) of 510 million people with vision impair ment from 
uncorrected presbyopia (appendix p 107). The strong 
association between age and vision impairment is presented 
for various severities of vision impairment in figure 1. For 
example, in terms of global blindness, 1·67 (1·36–2·01) 
per 1000 people aged 30–34 years, 6·24 (4·78–7·90) per 
1000 people aged 50–54 years, 27·8 (22·2–34·7) per 
1000 people aged 70–74 years, and 68·6 (55·5–85·9) 
per 1000 people aged 90–94 years, were blind (appendix 
p 107). Crude prevalence of vision impairment categories by 
age group are given in the appendix (p 107).
To compare patterns and trends in the prevalence of 
vision impairment without being confounded by the age 
structure, we calculated age­standardised prevalence, 
focusing on older adults (aged ≥50 years), who had the 
largest burden of vision impairment (appendix p 108). 
In 2020, the age­standardised prevalence of blindness 
in this age group was 18·5 (95% UI 15·7–21·1) per 
1000 people. Regions where prevalence of blindness 
exceeded 30 cases per 1000 people included southern 
(30·9 per 1000), eastern (40·0 per 1000), and western 
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(42·2 per 1000) sub­Saharan Africa; south Asia (35·3 per 
1000); and southeast Asia (37·2 per 1000). By contrast, 
the prevalence of blindness was less than 5 cases 
per 1000 people in the high­income North America (3·98 
per 1000), high­income Asia Pacific (4·24 per 1000), and 
Australasia (4·87 per 1000).
Global age­standardised prevalence of moderate and 
severe vision impairment was 112 (95% UI 99·0–126) 
cases per 1000 people in this older age group (appendix 
p 108). The region with the highest prevalence of moderate 
and severe vision impair ment was south Asia (229 cases 
per 1000 people) with a considerably higher prevalence 
 Blindness Moderate and severe vision impairment
Cases (thousands) Age-standardised prevalence 
(per 1000)
Cases (thousands) Age-standardised prevalence 
(per 1000)
2020 Percentage 
change 
1990–2020
2020 Percentage 
change 
1990–2020
2020 Percentage 
change in cases 
1990–2020 
2020 Percentage 
change 
1990–2020 
Global 43 300 
(37 600 to 48 400)
50·6% 
(47·8 to 53·4)
5·25 
(4·58 to 5·87)
–27·0% 
(–27·8 to –26·1)
295 000 
(267 000 to 325 000)
91·7% 
(87·6 to 95·8)
35·8 
(32·4 to 39·2)
1·1% 
(0·6 to 1·6)
Andean Latin America 349 
(301 to 398)
64·0% 
(57·7 to 70·3)
5·96 
(5·12 to 6·81
–41·6% 
(–44·2 to –39·5)
2760 
(2510 to 3020)
117·0% 
(110·0 to 125·0)
45·6 
(41·4 to 49·9)
–3·9% 
(–5·6 to –2·2)
Australasia 68·9 
(59·1 to 78·8)
71·0% 
(61·6 to 81·9)
1·48 
(1·27 to 1·68)
–19·3% 
(–22·5 to –16·0)
750 
(679 to 821)
78·0% 
(70·1 to 85·8)
20·3 
(18·4 to 22·3)
1·1% 
(–1·8 to 4·3)
Caribbean 260 
(221 to 296)
43·6% 
(40·6 to 46·8)
4·96 
(4·24 to 5·63)
–27·6% 
(–28·9 to –26·3)
1550 
(1410 to 1700)
63·8% 
(59·1 to 68·2)
30·6 
(27·8 to 33·5)
–3·7% 
(–4·9 to –2·3)
Central Asia 301 
(256 to 344)
21·9% 
(18·2 to 25·2)
4·07 
(3·47 to 4·67)
–24·3% 
(–25·8 to –23·0)
2950 
(2660 to 3270)
50·2% 
(46·8 to 53·5)
36·7 
(33·2 to 40·4)
–3·8% 
(–5·1 to –2·6)
Central Europe 327 
(280 to 373)
15·6% 
(12·3 to 19·5)
1·69 
(1·46 to 1·91)
–19·5% 
(–21·0 to –18·1)
3950 
(3490 to 4420)
30·3% 
(26·6 to 34·0)
21·7 
(19·5 to 24·1)
–2·4% 
(–3·2 to –1·6)
Central Latin America 1270 
(1100 to 1420)
76·0% 
(71·4 to 80·1)
5·09 
(4·41 to 5·72)
–38·7% 
(–39·9 to –37·6)
9840 
(8910 to 10800)
115·0% 
(108·0 to 122·0)
38·4 
(34·8 to 42·0)
–5·8% 
(–6·5 to –5·1)
Central sub-Saharan Africa 287 
(247 to 327)
88·1% 
(82·8 to 93·9)
4·86 
(4·14 to 5·54)
–25·8% 
(–27·7 to –23·5)
2010 
(1810 to 2230)
137·0% 
(131·0 to 142·0)
29·0 
(25·8 to 32·3)
–3·0% 
(–5·0 to –0·8)
East Asia 9090 
(7890 to 10300)
71·0% 
(62·3 to 79·8)
4·66 
(4·12 to 5·23)
–25·1% 
(–27·6 to –22·2)
53 900 
(47 800 to 60 400)
144·0% 
(135·0 to 152·0)
27·8 
(24·9 to 30·7)
10·7% 
(9·5 to 12·0)
Eastern Europe 790 
(690 to 890)
–3·4% 
(–5·7 to –0·8)
2·44 
(2·14 to 2·74)
–24·9% 
(–26·1 to –23·7)
11 100 
(9860 to 12 300)
16·3% 
(14·3 to 18·4)
36·4 
(32·8 to 40·1)
–1·7% 
(–2·5 to –1·0)
Eastern sub-Saharan Africa 1970 
(1740 to 2200)
70·9% 
(68·0 to 73·8)
10·7 
(9·24 to 12·0)
–26·7% 
(–27·6 to –25·7)
7010 
(6380 to 7670)
115·0% 
(112·0 to 118·0)
32·5 
(29·4 to 35·6)
–6·9% 
(–7·9 to –6·0)
High-income Asia Pacific 535 
(470 to 597)
43·5% 
(35·1 to 53·3)
1·45 
(1·28 to 1·62)
–26·9% 
(–28·6 to –25·2)
5340 
(4790 to 5860)
69·1% 
(60·1 to 78·9)
17·7 
(16·0 to 19·4)
0·7% 
(–0·3 to 1·5)
High-income North America 712 
(626 to 801)
71·0% 
(67·5 to 74·9)
1·24 
(1·09 to 1·39)
0·3% 
(–0·6 to 1·2)
7440 
(6750 to 8110)
50·2% 
(46·9 to 53·4)
16·0 
(14·4 to 17·5)
0·2% 
(–0·5 to 0·8)
North Africa and Middle East 3090 
(2650 to 3520)
53·0% 
(49·5 to 56·9)
7·00 
(5·93 to 8·02)
–41·5% 
(–42·7 to –40·3)
21 800 
(19 900 to 23 900)
110·0% 
(104·0 to 115·0)
43·1 
(39·1 to 47·2)
–6·1% 
(–7·3 to –4·5)
Oceania 39·3 
(33·8 to 44·6)
76·5% 
(71·9 to 81·4)
5·54 
(4·71 to 6·31)
–23·8% 
(–25·5 to –21·8)
385 
(349 to 425)
123·0% 
(118·0 to 128·0)
49·3 
(44·6 to 54·0)
–1·0% 
(–3·1 to 1·2)
South Asia 11 900 
(10 400 to 13 400)
37·3% 
(33·5 to 41·2)
8·95 
(7·80 to 10·1)
–46·7% 
(–47·5 to –45·8)
96 200 
(86 400 to 107 000)
96·9% 
(92·7 to 102·0)
64·4 
(57·9 to 71·3)
–13·5% 
(–14·5 to –12·6)
Southeast Asia 5950 
(5160 to 6680)
46·1% 
(43·1 to 49·1)
10·0 
(8·71 to 11·3)
–38·9% 
(–39·9 to –38·0)
28 800 
(26 500 to 31 100)
92·4% 
(87·2 to 97·2)
46·5 
(43·0 to 50·1)
–7·0% 
(–8·8 to –5·0)
Southern Latin America 158 
(136 to 180)
32·7% 
(28·1 to 36·9)
1·93 
(1·66 to 2·18)
–28·3% 
(–30·8 to –26·2)
2120 
(1920 to 2310)
56·3% 
(51·9 to 60·7)
28·1 
(25·5 to 30·7)
–2·2% 
(–4·2 to –0·3)
Southern sub-Saharan Africa 477 
(415 to 532)
45·4% 
(42·0 to 48·6)
8·24 
(7·18 to 9·21)
–28·6% 
(–30·0 to –27·0)
1560 
(1410 to 1710)
79·4% 
(75·2 to 83·4)
23·9 
(21·7 to 26·2)
–2·7% 
(–3·7 to –1·8)
Tropical Latin America 1780 
(1560 to 1990)
91·5% 
(85·4 to 97·6)
7·40 
(6·49 to 8·28)
–27·6% 
(–28·4 to –26·8)
10 300 
(9350 to 11 300)
87·8% 
(80·7 to 95·2)
43·6 
(39·5 to 47·6)
–4·5% 
(–5·3 to –3·8)
Western Europe 1530 
(1320 to 1760)
24·0% 
(19·3 to 29·2)
1·78 
(1·55 to 2·00)
–23·9% 
(–25·0 to –22·7)
15 400 
(13 900 to 16 900)
36·5% 
(32·9 to 40·1)
23·9 
(21·6 to 26·2)
–2·1% 
(–2·8 to –1·3)
Western sub-Saharan Africa 2350 
(2070 to 2640)
69·0% 
(66·1 to 72·4)
11·1 
(9·52 to 12·6)
–27·3% 
(–28·0 to –26·4)
9860 
(8940 to 10 800)
124·0% 
(122·0 to 127·0)
40·6 
(36·4 to 45·0)
–3·4% 
(–4·0 to –2·8)
Data in parentheses are 95% uncertainty intervals. Count data are presented to three significant figures, and percentage changes to one decimal place. Crude prevalence rates are in the appendix (p 105).
Table 1: Number of cases and age-standardised prevalence of blindness and moderate and severe vision impairment in 2020 and change since 1990, all ages
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than the next two regions of highest prevalence, Oceania 
(173 per 1000) and southeast Asia (154 per 1000). Mild 
vision impairment affected 77·2 (66·2–88·2) people per 
1000 of the global population in this older age group, with 
highest prevalence noted in southeast Asia (117 per 1000) 
and south Asia (108 per 1000; appendix p 108).
Change in age­standardised prevalence of mild vision 
impairment, moderate and severe vision impairment, 
and blindness in adults aged 50 years and older between 
1990 and 2020 is shown in figure 2, globally and by 
region and sex; numbers affected, and change in age­
standardised prevalence are shown in the appendix 
 Mild vision impairment Vision impairment from uncorrected presbyopia
Cases (in thousands) Age-standardised prevalence 
(per 1000) 
Cases (in thousands) Age-standardised prevalence 
(per 1000) 
2020 Percentage 
change 
1990–2020
2020 Percentage 
change 
1990–2020
2020 Percentage 
change 
1990–2020
2020 Percentage 
change 
1990–2020
Global 258 000 
(233 000 to 285 000)
62·8% 
(57·5 to 68·1)
32·0 
(28·9 to 35·4)
–3·9% 
(–4·4 to –3·4)
510 000 
(371 000 to 667 000)
124·4% 
(120·1 to 129·2)
59·7 
(43·6 to 78·1)
6·3% 
(4·8 to 7·8)
Andean Latin America 2140 
(1930 to 2370)
94·4% 
(87·1 to 103·0)
35·2 
(31·7 to 39·1)
–8·6% 
(–10·1 to –6·8)
2740 
(1980 to 3680)
174·0% 
(159·0 to 191·0)
47·2 
(34·0 to 63·5)
–4·5% 
(–9·2 to 1·2)
Australasia 427 
(382 to 475)
71·8% 
(64·3 to 79·7)
11·6 
(10·4 to 12·9)
–2·9% 
(–5·4 to 0·3)
324 
(219 to 454)
58·5% 
(21·8 to 94·0)
6·62 
(4·42 to 9·31)
–25·1% 
(–42·7 to –9·5)
Caribbean 1730 
(1550 to 1920)
49·1% 
(44·9 to 53·3)
34·6 
(31·2 to 38·3)
–9·7% 
(–11·0 to –8·4)
2690 
(1950 to 3630)
91·2% 
(82·3 to 99·2)
50·6 
(36·7 to 68·0)
–6·7% 
(–11·0 to –2·6)
Central Asia 2200 
(1990 to 2440)
33·7% 
(30·0 to 37·2)
25·8 
(23·3 to 28·6)
–6·7% 
(–8·0 to –5·6)
5040 
(3590 to 6710)
62·4% 
(55·2 to 70·1)
65·4 
(46·6 to 87·0)
–3·8% 
(–7·4 to –0·2)
Central Europe 1980 
(1770 to 2220)
3·1% 
(–0·5 to 6·9)
13·7 
(12·3 to 15·2)
–9·0% 
(–9·8 to –8·1)
12 200 
(8740 to 16 500)
37·9% 
(30·3 to 44·8)
57·1 
(41·3 to 76·5)
–6·2% 
(–8·5 to –3·6)
Central Latin America 9110 
(8200 to 10100)
91·3% 
(83·4 to 99·5)
35·7 
(32·1 to 39·6)
–9·6% 
(–10·4 to –8·9)
13 700 
(9880 to 18 200)
199·0% 
(188·0 to 212·0)
54·8 
(39·7 to 73·0)
–1·8% 
(–4·3 to 1·0)
Central sub-Saharan Africa 3840 
(3430 to 4330)
115·0% 
(110·0 to 120·0)
38·3 
(34·4 to 42·5)
–10·2% 
(–12·0 to –8·3)
4710 
(3400 to 6310)
131·0% 
(117·0 to 148·0)
82·8 
(60·3 to 109)
–5·9% 
(–11·3 to 0·0)
East Asia 60 100 
(53 300 to 67 200)
53·4% 
(44·8 to 62·2)
34·1 
(30·6 to 37·8)
–10·3% 
(–11·1 to –9·6)
164 000 
(117 000 to 216 000)
146·0% 
(137·0 to 155·0)
73·8 
(53·2 to 97·0)
–2·2% 
(–4·8 to 0·7)
Eastern Europe 5340 
(4770 to 5960)
2·5% 
(0·1 to 4·9)
20·4 
(18·4 to 22·7)
–5·5% 
(–6·2 to –4·8)
26 000 
(18 800 to 34 400)
37·5% 
(33·4 to 41·5)
75·2 
(54·7 to 98·8)
9·1% 
(6·3 to 12·2)
Eastern sub-Saharan Africa 11 300 
(10 100 to 12 800)
94·0% 
(91·6 to 96·8)
34·9 
(31·6 to 38·6)
–14·1% 
(–14·9 to –13·2)
17 300 
(12 900 to 21 800)
114·0% 
(107·0 to 121·0)
95·2 
(71·8 to 120)
–7·9% 
(–10·7 to –4·9)
High-income Asia Pacific 9840 
(8670 to 11000)
58·8% 
(50·3 to 68·6)
33·4 
(30·3 to 37·1)
–5·5% 
(–6·1 to –4·7)
1980 
(1330 to 2810)
121·0% 
(93·0 to 147·0)
4·57 
(3·07 to 6·43)
0·2% 
(–3·7 to 4·5)
High-income North America 5140 
(4580 to 5700)
46·0% 
(42·3 to 49·7)
11·3 
(10·2 to 12·6)
–2·3% 
(–2·9 to –1·6)
4930 
(3480 to 6680)
77·3% 
(71·9 to 82·6)
7·94 
(5·67 to 10·8)
–0·3% 
(–2·7 to 1·9)
North Africa and Middle East 14 400 
(13 100 to 16 000)
80·5% 
(74·3 to 87·5)
26·8 
(24·2 to 29·7)
–10·1% 
(–10·9 to –9·2)
14 500 
(10 300 to 19 500)
136·0% 
(127·0 to 143·0)
32·1 
(22·9 to 43·5)
–14·0% 
(–16·8 to –11·5)
Oceania 376 
(338 to 421)
99·2% 
(94·6 to 104·0)
36·5 
(32·9 to 40·5)
–6·6% 
(–8·3 to –4·5)
403 
(284 to 544)
125·0% 
(109·0 to 145·0)
59·1 
(42·1 to 79·5)
–4·3% 
(–10·5 to 3·6)
South Asia 60 100 
(54 100 to 66 900)
73·9% 
(67·3 to 80·8)
38·3 
(34·5 to 42·6)
–12·1% 
(–12·8 to –11·4)
167 000 
(122 000 to 218 000)
136·0% 
(129·0 to 144·0)
110 
(80·9 to 143)
–4·0% 
(–6·2 to –1·4)
Southeast Asia 30 500 
(27 600 to 33 800)
49·5% 
(43·7 to 55·8)
48·0 
(43·5 to 53·0)
–11·9% 
(–13·0 to –10·9)
29 500 
(21 100 to 39 800)
129·0% 
(120·0 to 137·0)
47·5 
(34·0 to 63·6)
–9·6% 
(–12·3 to –6·7)
Southern Latin America 1290 
(1160 to 1440)
44·8% 
(39·7 to 49·9)
17·5 
(15·8 to 19·5)
–6·2% 
(–8·0 to –4·1)
489 
(332 to 696)
75·6% 
(62·2 to 90·9)
5·78 
(3·92 to 8·21)
–5·8% 
(–13·8 to 2·1)
Southern sub-Saharan Africa 2530 
(2290 to 2810)
53·7% 
(49·3 to 58·1)
35·8 
(32·3 to 39·6)
–9·1% 
(–10·0 to –8·2)
9570 
(7130 to 12 100)
126·0% 
(118·0 to 136·0)
150 
(113 to 190)
3·2% 
(–0·6 to 7·5)
Tropical Latin America 8490 
(7620 to 9460)
77·4% 
(69·7 to 85·2)
36·4 
(32·8 to 40·3)
–10·0% 
(–10·8 to –9·2)
8840 
(6250 to 12 000)
162·0% 
(148·0 to 176·0)
35·8 
(25·3 to 48·7)
–7·8% 
(–10·7 to –5·1)
Western Europe 10 900 
(9640 to 12 200)
32·7% 
(28·8 to 37·0)
17·3 
(15·6 to 19·1)
–5·1% 
(–5·9 to –4·4)
4490 
(3010 to 6340)
50·6% 
(43·7 to 59·5)
5·08 
(3·41 to 7·21)
–3·3% 
(–6·1 to 0·3)
Western sub-Saharan Africa 16 000 
(14 400 to 17 900)
124·0% 
(122·0 to 127·0)
44·0 
(39·8 to 48·7)
–7·1% 
(–7·5 to –6·5)
20 000 
(14 600 to 26 000)
148·0% 
(140·0 to 155·0)
92·6 
(68·1 to 120)
4·9% 
(2·7 to 6·9)
Data in parentheses are 95% uncertainty intervals. Count data are presented to three significant figures, and percentage changes to one decimal place. Crude prevalence rates are in the appendix (p 106).
Table 2: Number of cases and age-standardised prevalence of mild vision impairment and vision impairment from uncorrected presbyopia in 2020 and change since 1990, all ages, by region
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(p 108), as are numbers affected and crude prevalence 
of vision impairment categories in 1990 for all ages 
(appendix p 109).
Globally between 1990 and 2020, among older adults, 
we estimated that age­standardised prevalence of 
blindness decreased by 28·5% (95% UI –29·4 to –27·7; 
from 25·8 [22·2 to 29·6] cases per 1000 in 1990, to 18·5 
[15·7 to 21·1] cases per 1000 in 2020), with the decrease 
being larger among males (–33·2%, –34·0 to –32·3) than 
among females (–25·0%, –26·0 to –23·9). Change in 
crude prevalence for those aged 50 years and older for this 
period was –21·9% (–23·3 to –20·6) in females and 
–27·4% (–28·7 to –26 ·2) in males; and for all ages was 
4·6% (2·6 to 6·6) for females and –0·7 (–2·6 to 1·1) for 
males. This reduction among both sexes was noted in all 
regions, but in particular in south Asia, where a change of 
–47·6% (–48·4 to –46·9) was observed for both sexes 
combined in those aged 50 years and older. In this time 
period, for moderate and severe vision impairment, global 
estimated age­standardised prevalence among those aged 
50 years and older increased slightly by 2·5% (1·9 to 3·2; 
from 109 [96·7 to 123] cases per 1000 in 1990 to 112 
[99·0 to 126] cases per 1000 in 2020), and a more 
substantial increase was seen among females (4·27%, 
1·86 to 3·17) than among males (0·35%, –0·31 to 1·03). 
We found considerable inter­region variation in this 
change—eg, for both sexes combined, south Asia 
(–12·6%, –13·8 to –11·6) and southeast Asia (–7·7%, 
–10·0 to –5·2) had the most substantial decreases, 
whereas an increase of 8·5% (7·1 to 9·9) was found for 
east Asia. For mild vision impairment, age­standardised 
prevalence reduced slightly by 0·3% (–0·8 to –0·2; from 
77·8 [66·3–88·4] cases per 1000 in 1990 to 77·3 [66·2–88·2] 
cases per 1000 in 2020) globally and in all regions, with a 
reduction of 3·1% (–3·7 to 2·4) in males whereas the 
prevalence in females increased by 1·9% (1·2 to 2·5). For 
vision impairment from uncorrected presbyopia, we were 
not able to do global and inter­regional analyses due to 
sparsity of data.
By 2050, the number of people with blindness in the 
global population is predicted to increase to 61·0 million 
(95% UI 52·9–69·3). Moderate and severe vision 
impairment is predicted to affect 474 million (428–518) 
people, mild vision impairment to affect 360 million 
(322–400) people, and vision impairment from 
uncorrected pres byopia to affect 866 million (629–1150) 
people. A breakdown of estimates by sex is given in 
figure 3 and by region and sex in the appendix 
(pp 112–113).
GBD has published YLD data for 2019;23 therefore, the 
report and analyses that follow relate to 2019. Sense 
organ diseases form an aggregate of disability resulting 
from blindness and vision loss due to eye diseases (near 
vision loss, uncorrected refractive error, glaucoma, age­
related macular degeneration, cataract, and other vision 
loss), age­related and other hearing loss, and other sense 
organ diseases. These diseases resulted in 66·1 million 
(95% UI 45·1–93·0) YLDs or 7·7% (6·4–9·3) of total 
YLDs in 2019. Blindness and vision loss resulted in 
22·6 million (15·6–31·7) global YLDs in 2019, a 20·3% 
(18·9–21·9) increase since 2010; YLD data can be viewed 
through the GBD Compare tool.
When ranked against all causes of disease by YLDs in 
the Global Burden of Diseases, Injuries and Risk Factors 
Study 2019, blindness and low vision ranked eighth 
(contributing 3·8% [95% UI 3·0–4·9] of all YLDs) in the 
aged 50–69 years age group for both sexes (following, in 
order of the highest ranking, low back pain, diabetes, 
age­related hearing loss, other musculoskeletal causes, 
depressive disorders, osteoarthritis, and headache 
disorders), and fourth (contributing 6·4% [5·4–7·4] of all 
YLDs) in the aged 70 years and older age group (following, 
in order of the highest ranking, age­related hearing loss, 
diabetes, and low back pain).
Discussion
In 2013, the World Health Assembly adopted resolution 
66.4, which included Towards universal eye health: a global 
action plan 2014–2019.3 The vision was “A world in which 
nobody is needlessly visually impaired, where those with 
unavoidable vision loss can achieve their full potential 
and where there is universal access to comprehensive eye 
care services.”3 The primary indicator of the global action 
plan was the prevalence and causes of vision impairment, 
which included moderate and severe vision impairment 
and blindness. The global action plan also set a specific 
global target: a reduction in the prevalence of avoidable 
vision impairment of 25% by 2019 from the baseline 
of 2010. Has this target been met? In 2010, of the 
Figure 1: Estimated age-specific prevalence of distance vision impairment (A) and vision impairment from 
uncorrected presbyopia (B), by sex, in 2020
Solid lines show sex-specific prevalence estimates, with shaded areas indicating 95% uncertainty intervals.
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global population of 6·9 billion people, we estimate 
37·0 million people were blind and an additional 
233·5 million people had moderate and severe vision 
impairment. Hence, the prevalence of vision impairment, 
as defined by the global action plan, was 3·92%. In the 
current study, we estimate that there are 43·3 million 
people who are blind and an additional 295 million 
people with moderate and severe vision impairment in a 
total world population of 7·79 billion in 2020. Hence, the 
prevalence of vision impairment in 2020, as defined by 
the global action plan, was 4·34%. Although in this study 
we are not specifically addres sing so­called avoidable 
vision impairment that the global action plan specified in 
its global target (the causal breakdown into avoidable and 
unavoidable vision impairment is covered in another 
report by our group27), in terms of crude prevalence, the 
target has clearly not been met. The increase in 
prevalence is determined by at least two variables: the 
need and the provision of services. Factors contributing 
to the extent of provision of services include the extent of 
services available (dependent on the availability of limited 
resources allocated to blindness alleviation vs other 
competing priorities); awareness of the population that 
the services are available; perceived need for services 
among the population (including assurance of quality); 
and the extent to which barriers such as cost of travel, 
fees, and fears can be overcome. Sustainability of the 
efforts put into provision of these services is one of 
many long­term needs. Although the observed decrease 
in age­adjusted burden of vision impairment suggests 
systematic improvements are occurring, more improve­
ments are needed to alleviate the problem of vision 
impairment to the extent envisioned in the global action 
plan. These measures would need to address both the 
supply of services and factors affecting demand for 
the services.
However, encouragingly, the age­adjusted prevalence of 
blindness was estimated to have reduced by 27·0% 
(95% UI –27·8 to –26·1) globally between 1990 to 2020. 
Conversely, the age­adjusted prevalence of moderate 
and severe vision impairment increased slightly (1·1%, 
0·6 to 1·6). This slight increase is probably due to 
resources for cataract being directed to more severe 
disease (cataract surgical coverage is substantially 
higher for eyes with visual acuity of less than 3/60 than 
for eyes with a visual acuity of less than 6/18, especially in 
the most recent RAAB surveys and in low­income 
and middle­income countries,5 although the causal 
contribution to the change in age­standardised prevalence 
has been investigated in another report by our group27).
As we noted in the 2015 estimates,4 approximately 
75% of the global population who are blind are aged 
50 years and older. Although the growth rate of the 
world’s population has been decreasing since the late 
1960s, the world’s population has continued to increase, 
predicted to reach an inflection point in 2020. The current 
Figure 2: Estimated percentage change in age-standardised prevalence of blindness, moderate and severe vision impairment, and mild vision impairment 
among individuals aged 50 years and older, by region and sex, 1990–2020
Bars show the percentage change in age-standardised prevalence, with errors bars indicating 95% uncertainty intervals. 
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total population of 7·79 billion is expected to plateau 
at approximately 11 billion by 2100.28 The rate of 
population growth remains especially high in the group 
of 47 countries designated by the UN as the least 
developed, including 32 countries in sub­Saharan Africa.28 
In 2018, for the first time in human history, people aged 
65 years or older outnumbered children younger than 
5 years.29 Between 2020 and 2050, the proportion of the 
world’s population aged 65 years or older is expected to 
double, from approximately 1 billion to 2 billion.28 The 
ageing of the world’s population will have critical 
ramifications on age­related diseases, including age­
related blindness from cataract, uncorrected refractive 
error, age­related macular degeneration, and glaucoma.
Furthermore, the increasing proportion of the world’s 
population that are now in the oldest age groups 
deserves specific attention. In this study, we found that the 
prevalence of blindness in those aged 90–94 years was 
more than 11 times greater than in those aged 50–54 years. 
However, we should be mindful that although the regions 
undergoing development with increasing life expectancies 
face the challenge of age­related vision impairment, the 
most under­developed and economically disadvantaged 
regions, particularly sub­Saharan Africa, still have the 
highest prevalence of blindness in older adults.
Another important finding made possible with the more 
granular data we used in this analysis than in previous 
analyses, was the sex difference in the vision impairment 
burden. The VLEG and others have previously noted a 
higher prevalence of vision impairment in women than in 
men, particularly in low­income and middle­income 
countries.4,29 The factors contributing to this disparity are 
complex and can be attributed to biological (eg, women 
tending to live longer than men and are more at risk of 
developing some conditions such as cataract) and social 
factors (eg, social discrimination that appears to result in 
more women having vision loss than men when no such a 
magnitude of difference in incidence of disease by sex is 
clearly seen). In the current study, we observed that, 
between 1990 and 2020, the age­standardised prevalence 
of blindness in older adults reduced by 25·0% in women 
and 33·2% in men. However, for mild vision impairment 
and moderate and severe vision impairment, the global 
age­standardised prevalence for women increased. These 
data provide evidence­based motivation to understand the 
region­specific reasons for the sex discrepancy and initiate 
strategies to close this gap.
The age­standardised prevalence of moderate and 
severe vision impairment in east Asia increased between 
1990 and 2020 by 10·7%. This increase is most likely 
related to the myopia epidemic that began approximately 
30 years ago in this region.30 It might also result from a 
reduction in the prevalence of blindness, with people 
who were formerly blind moving to the category of 
moderate and severe vision impairment because of 
residual or coexisting ocular disease or damage. An 
increase in progressive axial myopia has paralleled the 
increase in education levels during the past 30 years in 
parts of east Asia.30 In a similar way that trachoma was 
once described as a so­called disease of the crèche 
(preschool child care), converging evidence has indicated 
that myopia is largely a so­called disease of the classroom, 
especially the competitive classroom.30 Genetic factors 
have a relatively minor role.31 The recognition that 
myopia is driven largely by environ mental factors related 
to intensive schoolwork has motivated successful 
treatment strategies that increase time spent outdoors 
for schoolchildren.32 These simple and inexpensive 
strategies will need to be widely adopted, particularly as 
development and associated improvements in education 
levels increase over the coming decades.
Presbyopia was reported to affect more than 1 billion 
people globally in 2005; however, this estimate was 
based on robust data from only four countries (India, 
Tanzania, Brazil, and Timor­Leste).33 In response to the 
paucity of data, WHO developed a standardised protocol 
for asses sing the prevalence of vision impairment 
from uncor rected presbyopia.34,35 A 2018 meta­analysis 
esti mated that, in 2015, 826 million people had near 
vision impairment due to no, or inadequate, presby­
opic correction.36 The relative sparsity of data about 
uncorrected presbyopia remains problematic. Until 
2019, the International Classification of Diseases did 
not have a definition of near vision impairment. This 
Figure 3: Forecast of number of people affected by mild vision impairment (A), moderate and severe vision 
impairment (B), blindness (C), and vision impairment from uncorrected presbyopia (D), all ages by sex, 
1990–2050
Datapoints are estimates number of people affected in millions, with lines linking the datapoints and shaded areas 
indicating the 95% uncertainty intervals. 
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limitation prevents the presentation of meaningful 
analysis of the temporal change in prevalence of vision 
impairment from uncorrected presbyopia. However, it 
exemplifies the importance of surveys incorporating a 
near vision component to better understand future 
trends.
This study highlights the large burden of mild, 
moderate, and severe vision impairment that could 
become overwhelming as the global population ages in 
both high­income countries and low­income and middle­
income­countries. While low­income and middle­income 
countries are challenged with detecting and delivering 
care to those already in an advanced state of vision loss, 
high­income countries face service delivery challenges to 
manage chronic age­related eye diseases in an ageing 
population with increasing life expectancy.37
The VLEG contributed data on vision impairment 
prevalence to WHO’s recent World report on vision, based 
on the VLEG’s 2015 estimates.5 WHO recognises the 
challenges being faced and recommends that eye care 
become an integral part of universal health coverage.5 
Such integration would be beneficial, but impactful 
reduction in the prevalence of vision loss will also require 
concerted action targeting both avoidable blindness due 
to cataract and uncorrected refractive error and strategies 
to restrict vision impairment from chronic age­related 
diseases and diabetic eye disease.
The strengths of this updated review and analysis for 
2020 include the substantial addition of new data sources 
and the wider geographical region that these sources 
cover. In particular, the contribution of the RAAB surveys, 
most of which took place in low­income and middle­
income countries, has been enhanced by the extraction of 
data disaggregated into smaller age categories, which has 
greatly strengthened the fitting of age patterns to the data 
from these surveys. However, our study also had several 
limitations. For example, several regions, such as central 
sub­Saharan Africa, central and eastern Europe, and 
central Asia, still have little or no population­based data, 
so estimates in these regions rely on extrapolation from 
other regions. Sparse data also restricted our ability to 
estimate temporal trends. Few data were available for 
children, and although we were able to include data 
from the Refractive Errors Studies in Children, which 
involved robust population­based sampling,38 many 
studies containing data on children were done in school 
settings. Such reporting might lead to bias in countries 
with low school enrolment. Additionally, approximately 
15–20% of included sources reported best­corrected 
vision instead of presenting vision, and therefore we 
adjusted these data to the reference definition. These 
adjustments were based on data that matched presenting 
and best­corrected data. Because the uncertainty of this 
adjustment is carried forwards, these datapoints have 
wide uncertainty intervals, but were weighted accordingly 
in the Bayesian modelling. We describe inclusion criteria 
used when assessing potential sources of vision data in 
the appendix. During data processing, we applied data 
adjustments to studies that did not match our reference 
definition to make use of as much data as possible. For 
example, our reference definition is presenting visual 
acuity, so we adjusted best­corrected visual acuity 
systematically on the basis of the results of a regression 
analysis comparing the prevalence of the two methods. 
Our estimation tool (DisMod­MR) quantifies between­
study heterogeneity (the part of variance not ascribed to 
fixed effects or geographical random effects) and adds 
uncertainty based on that finding. Notably, this process 
does not preclude any remaining measurement error that 
we were unable to account for.
For the first time in our reports, we have incorporated 
YLDs into our analysis. Although VLEG remains 
concerned over the disproportionally low disability 
weights assigned to blindness and vision impairment,39,40 
these disabilities are responsible for 2·6% (95% UI 
2·2–3·2) of total global YLDs, and are highly ranked 
against other age­related diseases.24 Younger people with 
blindness (and moderate and severe vision impairment) 
are more likely to have an irreversible cause of vision 
impairment than older people. This fact and the longer 
remaining life expectancy mean that blindness and 
vision impairment at a younger age are potentially more 
important than at an older age in terms of YLDs.
The WHO World report on vision observes that 
“Concerted action during the past 30 years has yielded 
many successes: global advocacy efforts have been 
launched; World Health Assembly resolutions adopted; 
and actions plans implemented. Recent scientific and 
technological developments promise to further accelerate 
these advances. Nonethe less, progress is not keeping 
pace with population eye care needs.”5 We are encouraged 
by the reduction in the global prevalence of age­related 
blindness but the increase in the crude prevalence of 
blindness is sobering. This evidence indicates that we 
face enormous challenges as the global population grows 
and ages. Strategic and cost­effective approaches targeting 
cataract and uncorrected refractive error need renewed 
impetus and clever use of emerging technologies towards 
solving the problem of global vision impairment should 
be a health priority. Because most cases of vision 
impairment require individual­level clinical care, training 
and sustainable delivery system development require 
renewed attention.
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